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Background: This study examines the use of new psychoactive substances (NPS) and the harm 
reduction response in six Eurasian countries: Belarus, Moldova, Serbia, Kazakhstan, 
Kyrgyzstan, and Georgia.  The aim is to identify current patterns of NPS use and related harms 
in each country through recording the perspectives and lived experience of people who use 
drugs and people who provide harm reduction services in order to inform the harm reduction 
response.  
 
Methodology: The study involved desk-based research and semi-structured interviews/focus 
groups with 124 people who use drugs and 55 health and harm reduction service providers 
across the six countries.  
 
Results: People who use drugs in all countries were aware of NPS, primarily synthetic 
cathinones and synthetic cannabinoids. NPS users generally reflected two groups: those with 
no prior history of illicit drug use (typically younger people) and those who use NPS on an 
occasional or regular basis due to the lack of availability of their preferred drug (primarily 
opiates). In many cases, these respondents reported they would not use NPS if traditional 
opiates were available. Common factors for choosing NPS included cost and accessibility.  
Respondents in most countries described NPS markets that use the DarkNet and social media 
for communication, secretive methods of payment and hidden collection points.  A recurring 
theme was the role of punitive drug policies in driving NPS use and related harms. 
Respondents in all countries agreed that current harm reduction services are important but 
needed to be enhanced and expanded in the context of NPS.   
Conclusions: The study identified patterns and drivers of NPS use, risk behaviours and drug 
related harms.  It identified gaps in the current harm reduction response, particularly the 
needs of non-injectors and overdose response, as well as harmful effects of punitive drug 
policies. These findings may inform and improve current harm reduction services to meet the 
needs of people who use NPS. 
 
Keywords: New Psychoactives Substances, NPS, harm reduction, Eurasia, Belarus, Moldova, 




This study examined the use of new psychoactive substances (NPS) and the harm reduction 
response in six Eurasian countries – Belarus, Moldova, Serbia, Kazakhstan, Kyrgyzstan, and 
Georgia. The research engaged people who use drugs in order to record their lived experience 
of NPS use, NPS markets and NPS-related harms.  Researchers also engaged with people 
providing harm reduction and health services, to draw out their experiences of responding to 
NPS use. This study represents the first detailed, multi-country investigation of NPS use and 
harm reduction undertaken in Eurasia, one that focusses on the community response among 
people who use drugs and service providers. The results supplement the scarce data on the use 
of NPS in these countries and the region as a whole, and may contribute to building a more 
accurate picture of the use of new psychoactives that can inform policy change and the harm 
reduction response.  
The United Nations Office on Drugs and Crime defines new psychoactive substances as 
“substances of abuse, either in a pure form or a preparation, that are not controlled by the 1961 
Convention on Narcotic Drugs or the 1971 Convention on Psychotropic Substances, but which 
may pose a public health threat” (1). In other words, these are synthetic substances designed to 
mimic the psychoactive effects of more traditional illicit drugs. While not all new 
psychoactives are truly “new” substances (1), their presence in the illicit drug marketplace is 
an attempt to “outwit drug laws by producing drugs that are not controlled” under criminal law 
(2).  Some countries have criminalised new psychoactives in domestic law, even though they 
are not controlled under the international drug treaties (11). In response, substances continue 
to have their chemical composition “tweaked” to try to skirt regulation (11), creating what has 
been described as a “cat-and-mouse game between legislation and clandestine 
laboratories…with new designer stimulants replacing those outlawed almost as soon as 
legislation passes”. (21) 
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Most new psychoactives fall into two general categories. Synthetic cathinones mimic the 
effects of amphetamines, cocaine and ecstasy, and are typically ingested orally, inhaled or 
injected (3, 21).  Synthetic cannabinoids mimic the effects of cannabis, and are typically mixed 
with tobacco or other herbal mixtures and smoked (3, 20).  In Western Europe, the most popular 
new psychoactives are methcathinones and phenethylamines, drugs that mimic the effects of 
cocaine and ecstasy (4).  For this reason, discourse on NPS use in Western Europe has tended 
to focus on young people using new psychoactives in nightlife settings, clubs or music festivals 
(5, 6, 7, 8, 10).   
Anecdotal data and reports from civil society organisations across Central and Eastern Europe 
and Central Asia (CEECA) collected by the Eurasian Harm Reduction Association (EHRA) 
indicate that NPS use is increasing in many countries in the region, particularly among people 
who inject drugs.  With some important exceptions (14, 21), vulnerable or marginalised people 
who use drugs, and people who inject drugs, do not figure prominently within the Western 
European research on NPS use and harms. For example, of the more than 3000 NPS users 
surveyed in a 2019 study across six European countries (Germany, Hungary, Ireland, the 
Netherlands, Poland and Portugal), less than three hundred were identified as “socially 
marginalised users”, the vast majority of these being in Hungary and Poland, the eastern region 
of the European Union (8).  The anecdotal reports gathered by EHRA on increasing NPS use 
among people who inject appear consistent with the data drawn from Hungary and Poland in 
the above study (8), and is a situation also reported by other pan-European non-governmental 
organisations (9).   
New psychoactive substances have been associated with various health harms (20). NPS 
injecting has been linked with increased unsafe injecting practices (12, 14, 15, 20) and 
increased hepatitis C and/or HIV prevalence (22), particularly in Eastern European countries 
(12, 15).  Synthetic cathinones are described as producing a short-lived euphoria, leading to 
5 
 
more frequent injecting practices (20). It is generally assumed that most people who inject NPS 
have a previous history of injecting more traditional illicit drugs (20), although some research 
has documented people initiating injecting with NPS (14).   
Harms from the use of synthetic cannabinoids are also well documented (23), including in 
Eastern Europe (20).  These include physical effects such as increased heart rates and blood 
pressure, sometimes leading to strokes or heart attacks, as well as psychological harms such as 
psychosis (23). Both synthetic cathinones and synthetic cannabinoids have been linked to cases 
of overdose and poisoning (16, 17, 18, 19, 23).   
These developments create new challenges for harm reduction services, which have been 




The study was a partnership between EHRA and the School of Law, Swansea University, 
UK.  The six countries were selected for three reasons. (a) Feedback from communities of 
people who use drugs and civil society organisations in these countries indicated the need to 
examine NPS use. (b) The lack of comprehensive information on NPS use and related harms 
in each country. (c) The six countries represent four distinct Eurasian regions: Kazakhstan 
and Kyrgyzstan (Central Asia region); Georgia (Caucasus region); Serbia (South-Eastern 
Europe region) and Belarus and Moldova (Eastern Partnership neighbours).   
Stage 1 of the research consisted of desk-based research to survey and collate the available 
national data on NPS (official reports, media, peer-reviewed publications, literature not 
indexed in medical databases, documents from national government and regional/international 
organisations). Desk-based research informed preparation of the questions for key respondents, 
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who included people who use drugs, harm reduction service providers and medical 
professionals. Stage 2 consisted of semi-structured interviews and/or focus groups with key 
respondents, and compiling and analysing the data collected.  
 
Data collection 
EHRA is a network uniting 303 members in CEECA region, and the researchers used this 
network to identify and engage key respondents in each country. As the study aimed to gather 
information directly from people who use drugs, the researchers engaged organisations 
providing harm reduction services in each country. These in-county organisations assisted the 
researchers to recruit people who use drugs to participate. The researchers also identified, 
where possible, country-level organisations of key affected populations, including MSM, sex 
workers, people who use drugs and young people. Where such organisations existed, they were 
invited to participate in interviews or focus groups. Where possible, the researchers sought to 
organise interviews or focus groups in more than one city or town to seek a better understanding 
the situation for NPS use in the country. 
Focus groups and interviews took place between April 2019 and June 2020. Eliza Kurcevič 
(EK) conducted interviews and focus groups in Kazakhstan and Kyrgyzstan. Due to the 
COVID-19 travel restrictions that came into force in early 2020, interviews in Kyrgyzstan were 
conducted online using Zoom or Skype. In Belarus, Moldova, Georgia and Serbia, the authors 
contracted qualified and experienced country-based researchers to conduct interviews and 
focus groups. These contracted researchers followed the methodology and framework 
established for the study, and were supervised by the authors, who analysed the data collected.  
Interviews and focus groups were conducted in Russian, Georgian, Serbian or Moldovan (as 
appropriate), and were audio-recorded and later transcribed.  
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Table 1: Respondents 




Sites of Interviews/Focus 
Groups 
Belarus 11 3 Minsk and Mogilev 
Moldova 12 15 Chisinau and Balti 
Georgia 23 12 Tbilisi 
Kazakhstan 40 15 Temirtau, Karaganda and 
Almaty 
Kyrgyzstan 20 5 Bishkek and Osh 
Serbia 18 5 Belgrade 
 
Ethical considerations 
The Ethical Review Committee of the School of Law at Swansea University Study reviewed 
and approved the research methodology and safeguards. All study participants were aged 18 
years or older and voluntarily agreed to take part. All were advised of the purpose of the 
research and what was expected from them as participants. Debriefing was conducted after 
each interview or focus group, including an opportunity for participants to identify concerns or 
areas for further inquiry.  
All participants provided prior written consent. Consent forms were securely stored and an 
identifying code given to each participant (“Participant A”, etc.) to ensure anonymity. All 
participant data was stored securely and only used only for the purpose of the project. The 
research followed the legal guidelines of the European Union General Data Protection 
Regulation (GDPR), and the standards of the Ethical Review Committee of the School of Law, 
Swansea University.  
The people who use drugs who participated in the study were given the choice of whether to 
take part in focus groups. They were informed that their decision would have no impact on 
their access to support groups or harm reduction services.  A member of the harm reduction 
service or peer group was available to provide support if required. Given the illegal status of 
NPS, researchers explained they would not ask details of individual NPS use but would instead 
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talk broadly about NPS use in the wider community of people who use drugs. It was explained 
that all participant information would be anonymised. Member checking was carried out 
following the collection of the data.  
 
Results 
Appearance of NPS in domestic markets 
 
According to respondents, NPS first appeared in Belarus in 2008 to 2009. Prior to that time, 
the main drugs consumed were opiates made from poppy seeds and poppy straws. Opiates 
remained the main psychoactive substances used in the early years of NPS availability. 
However, in January 2014, the President of the Republic of Belarus issued a decree expanding 
criminalisation of poppy seeds (24). The impact was to significantly reduce the availability of 
traditional opiates, and usher in a significant increase in use of new synthetic drugs, 
transforming the domestic drug market. By 2017, NPS occupied 40% of the illicit drug market, 
with opiates comprising just 10% (25). 
In Moldova, respondents identified various years when new psychoactives first appeared in the 
drug market. Some participants stated that this occurred as early as 2010, while others 
identified 2013–2014 and 2015—2016. The first media reports on NPS in Moldova were 
published in 2014 (26, 27).  
In Georgia, respondents reported synthetic cannabinoids started to appear in 2013–2014. From 
2018, the use of synthetic cathinones (“bath salts”) became widespread.  Media attention in 
2013—14 led to the adoption of 2014 legislation on new psychoactive substances, and to the 
amendment of the penal code to criminalise NPS production, purchase, storage and other 
activities (28). That same year, the Ministry of Internal Affairs launched the campaign “No to 
New Psychoactive Drugs – Lets Change Attitude Together” (28). 
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In Kazakhstan, respondents reported that new psychoactives first appeared in 2009–2010.  New 
psychoactives appeared earlier in Kazakhstan than many other countries in the region due to 
its borders with China and Russia, which manufacture a large proportion of NPS, which are 
trafficked to or through Kazakhstan. 
In Kyrgyzstan, respondents reported that new psychoactives first appeared in 2013, when 
synthetic cannabinoids entered the drug market. This was also the first year NPS use was 
reported in the national media (29). New psychoactive substances went unregulated by national 
laws for several years, and were widely used, especially among young people. In 2015, the 
government adopted a law banning synthetic drugs, including “spice” and other herbal smoking 
mixtures. As the availability of synthetic cannabinoids started disappearing, synthetic 
cathinones (“salts”) appeared on the drug market.  
In Serbia, respondents stated that NPS began in 2010–2011, but gained popularity in 2013—
14 when synthetic cannabinoids became widely available through “Smart Shops”.  Synthetic 
cannabinoids were legal at this time and particularly popular among young people. Synthetic 
cathinones—specifically mephedrone (“meow meow”) — were also associated with this 
period, and were sold both to recreational users as MDMA and to opiate users who injected 
it.  However, after changes to legislation in 2015, the use of both synthetic cathinones and 
synthetic cannabinoids decreased. 
Types of NPS used and Common Slang Names 
 
Respondents in each country were asked to identify the most common new psychoactives in 
circulation, as well as the common names used for them. 
 
Country Common NPS Used and Slang Names 
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Belarus Synthetic cathinones (“salts”) and synthetic cannabinoids (“spice”) were the most 
common types of new psychoactives identified. Slang names for synthetic 
cathinones included Alpha-PVP (available in various colours); “Sabaka” (which 
means “dog” in English); Mephedrone (also called “Mefer”); “Black Mamba”; 
and “Dosia,” “Daska,” “Kedy,” “Krasofki,” “Skorost,” and “Speed” (for 
amphetamine-type substances). For synthetic cannabinoids, slang names 
included smoking mixtures, “Ligalka”, “Liga” and “Ximlo”. 
Moldova Respondents identified a number of common new psychoactives including: 
Mixes; Spice; Skorost (“speed” in English); Mephedrone; PVP; Energetics; 
Speed; JWH (a synthetic cannabinoid). 
Georgia The most frequently consumed substances were identified as Alpha-PVP, 
NBOMe, ketamine, synthetic cannabinoids (“spice”), mephedrone and speed.  
Some slang names for synthetic catinones included bath salts; salts; crystals; 
Alpha-PVP (or PVP); Muka (“flour” in Russian); Speed; Flakka; Mephedrone 
(or Mephe). Names for hallucinogens included Mark; Blotter; NBOMe; Gin; 
Acid. Names for synthetic cannabinoids included Bio; Bio-marijuana; Bio-
smoke; Bio-hashish; Spice; Chocolate; Cherry; Tea; Green; Black; White; 
Yellow. 
Kazakhstan Common slang names for synthetic cathinones included salts; bath salts; SK; 
Skorost (speed); Red dragon; Ruby; Muka (flour); Watermelon; Crystals; Alpha-
PVP; Mephedrone; Meow; 4-MMC; meph. Common names for synthetic 
cannabinoids included JWH or Dzhivik; Spice; Chamomile; St. John’s Wort; 
Aqua; Shiza. 
Kyrgyzstan Respondents reported that new psychoactives were referred to in various ways. 
The primary method was to describe NPS by its form: salt (slang name: “solyaga” 
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or “solyara”); crystals; flour; sugar. The other was to call it by its chemical name: 
mephedrone (or “meph” for short); Alpha-PVP; although this was less common. 
The most common slang to describe NPS included SK (meaning salts); speed; 
cosmos; blue stone; snowy flour; Rahat; high; take-off; Chinese salts; bath salts. 
The other common way was to describe NPS by colour: blue, red, white, yellow, 
etc. 
Serbia Respondents were not entirely clear what constituted “new” psychoactives. 
However, the following substances were identified by as being “new” in the 
context of the Serbian drug scene; GHB/GBL (“G”); Synthetic cannabinoids 
(“Herbal incense”, “spice/”, “Black Mamba”); 2CB; PCP/3MEOPCP; Alpha-
PVP (PVP); Ketamine (K, Special K); Mephedrone (“Meow Meow”); Flex 
(synthetic cocaine); 25I-NBOMe  
 
 
Patterns of use 
 
In Belarus, synthetic cathinones were becoming the primary drug injected due to accessibility 
and cost. However, intravenous use was more likely to occur among people who had previously 
injected other opioids. In Moldova, the most common methods of NPS use were smoking, 
injecting and inhalation. Focus group participants stated NPS was more prevalent among young 
men and women under the age of 35 than among other age groups. These new consumers and 
younger consumers predominantly smoked or inhaled NPS.  In Georgia, NPS were consumed 
by smoking, sniffing, swallowing, injecting and sticking under or on top of the tongue 
(blotters). Putting drops in the eyes was common for hallucinogens (liquid acid). Injecting NPS 
use was more likely among people who had previously injected other drugs, including opioids. 
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In Kazakhstan, NPS were used both by people with a history of more traditional drug use and 
by people who started with NPS. However, the two groups usually differed in age and route of 
administration, and did not interact with each other. Among experienced and older users, the 
most common routes of administration were smoking and injecting. Younger people with no 
previous drug use history preferred smoking and snorting as these methods were simpler and 
required no additional preparation or special equipment/paraphernalia. However, some 
respondents reported that people who started by snorting or smoking NPS sometimes began 
injecting after 3–4 months because of an increased tolerance.  
In Kyrgyzstan, the most common methods of using NPS were smoking (through pipettes, 
bulbs) and snorting. Respondents reported NPS use was common among young people, 
including school and university students. This group was described as being afraid of injecting, 
and preferring to use NPS in ways other than intravenously, such as by wrapping substances in 
paper and taking them orally (so-called “bombs”). Young people were described as having a 
culture of sharing information about NPS (where to purchase, which were the best, how to use, 
etc.). There was also a culture of using in groups, called “marathon gangs” because the group 
will use NPS for several days in a row.   
In Serbia, the most common methods of consuming NPS were smoking, snorting and oral 
ingestion. NPS consumer fell into two primary groups.  The first were members of the MSM 
community who used GHB/GBL and other substances in the context of social and sexual 
activities, to reduce physical and socio-cultural inhibitions. All study respondents from the 
MSM population were active users of GHB. The second group were young people used NPS 
in recreational settings, such as parties, festivals or similar events. This group was comprised 
both people who knowingly consumed NPS and people who believed they were taking a 
more traditional illicit substance such as MDMA or cocaine.  
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With the exception of Serbia, all the countries reported injecting NPS to be common.  In all 
these cases, injecting was more likely to occur among people with a previous history of 
injecting other drugs, particularly opiates.  In Moldova, for example, respondents estimated 
that synthetic cathinones represented more than 70% of cases of all injecting drug use, 
resulting in significantly reduced use of other opioids because of substitution with these new 
injectable substances. However, in Serbia intravenous use of NPS appeared to be very rare, 
and respondents reported no examples of injecting in their networks. Respondents from the 
MSM community observed that injecting (so-called “slamming”) was not as popular in 
Serbia as in some other European countries. Explanations for this included the lower 
purchasing power in the country and the stigma surrounding injecting drug use in Serbian 
society. Respondents in Serbia reported that people who inject drugs (primarily opiate users) 
and sex workers generally preferred to use traditional illicit substances or prescription drugs. 
While opiate users might consume NPS on occasion, this would typically occur on a 
situational basis when dealer had it available and offered it, not because the opiate users 
actively sought out NPS. 
Smoking NPS was reported to be common in most counties among both cohorts.  Almost 80% 
of respondents in Moldova reported using “spice” as a smoking mixture. In Georgia, the 
synthetic cannabinoid, “Bio”, was typically sold in powder or crystal form, and mixed with 
tobacco and smoked. Participants reported that “Bio” had a short-term effect that usually lasted 
10 minutes. For this reason, it could be smoked 50 or more times a day. Participants in Serbia 
reported that the use of synthetic cannabinoids was very popular for a period, even among 
people who used opiates, because they were legal, affordable and inexpensive. However, this 
popularity drastically diminished when synthetic cannabinoids were criminalised. 
Participants in Georgia, Serbia and Kygyzstan identified poly-drug use as common among 
people who use NPS, and that new psychoactives typically were used in combination with other 
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drugs.  In Georgia for example, common drug combinations identified included: Ketamine + 
Speed + Amphetamine (so-called “Trinity of Berlin”); Alpha-PVP + Bio-marijuana; Alpha-
PVP + Ketamine; Speed + Ketamine; Amphetamine + Bio-marijuana; Ecstasy/MDMA + Bio-
marijuana; Ecstasy/MDMA + Speed; LSD/NBOMe + Mushrooms + Bio-marijuana (so-called 
“Candy Flip”). In Kyrgyzstan, NPS were often used in combination with pharmaceutical drugs 
rather than with illicit drugs. In Serbia, NPS were commonly consumed in combination with 
amphetamines, cocaine, ecstasy, alcohol and cannabis. There were several reasons identified 
for the popularity of drug combinations: to prolong or intensify the drug’s effect; to change one 
drug’s effect by adding another (e.g. a stimulant effect with a hallucinogenic effect); to 
accelerate the effects of a drug (to reach “kick-in” sooner) or to handle coming down or reduce 
drug hangovers.  
 
Dosage and Potency 
In Belarus, respondents stated that synthetic cannabinoids (“spice”) had grown in potency over 
the past decade.  One participant noted that ten years ago, one gram of reagent could be mixed 
with herbs to produce seven grams of smoking mixture. Today, one gram of reagent produced 
30—40 grams of smoking mixture.  For people who used synthetic cathinones, the daily dosage 
varied greatly depending on the substance, its quality and the individual’s tolerance. For 
example, one gram of “salts” such as “Alpha-PVP” and “Sabaka” was generally sufficient for 
20—25 injections. Because two or more people typically used together, this equated to 10—
15 injections per night/per person. From one gram of mephedrone it was possible to prepare 
3—4 injections. Respondents described the effects of mephedrone as short lasting, leading to 
a greater number and frequency of injections. Participants used the term “toler” to describe 
growing tolerance of NPS over the course of several days of use. For example, if a person used 
0.5 gram of NPS on the first day, he or she would likely need 2.5 grams by the fifth day. 
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In Moldova, virtually all participants reported that one gram of “Bio” marijuana was enough 
for 100 (or even more) doses, depending on potency (black “Bio” was identified as the most 
potent and green “Bio” the least).  
In Georgia, participants reported that one gram of synthetic cathinones prepared up to 30–40 
injections, 20–25 smoking doses and 10–20 sniffing doses. Participants noted that injecting 
and smoked/sniffed dosing occurred every 40-60 minutes.  NPS dosage was described as being 
dependent on the person’s experience and tolerance, with new or less experienced people using 
lower doses than more experienced users. On average, participants reported that 10–15 
injecting or smoking/sniffing episodes per day by an individual.  
In Kazakhstan, respondents could not identify a typical daily dose. NPS tolerance was 
described as growing quickly, and the euphoria experienced in one dose as short lasting. As a 
result, NPS were commonly used until finished and a person purchased more. In Kyrgyzstan, 
respondents also could not identify a typical daily dosage, although most agreed that NPS were 
used continuously until there was none left. The effect of NPS was described as being a quick, 
short-lasting euphoria. If a person or group purchased a larger amount of a substance, it could 
be used for 5–10 days or more without breaks until it was finished.  
 
Reasons for choosing NPS 
 
The low price of NPS was among the most common factors identified for the popularity of new 
psychoactives (Belarus, Moldova, Georgia, Kazakhstan, Kyrgyzstan), particularly among 
younger people unable to afford more traditional drugs.  In Belarus, for example, respondents 
said that heroin, opium, hashish and cannabis were five to ten times higher than the price of 
NPS.  Related to the issue of cost was that of potency. A person could obtain more doses from 
one gram of NPS than a gram of more traditional illicit drugs.  
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Along with pricing, the inaccessibility of traditional illegal drugs was the other most commonly 
cited reason for using NPS (in all countries other than Serbia). This was particularly the case 
among respondents with previous drug use histories (typically injecting drug use) who 
substituted new psychoactives for their preferred drug of choice due to either high cost or 
general lack of availability in the market.  In Moldova, respondents stated NPS were used as a 
temporary substitute for illicit drugs such as opium or heroin that were not accessible. 
Respondents in Kazakhstan and Kyrgyzstan, described heroin as disappearing from the drug 
market, and NPS use occurred because people lacked other options. Respondents in Belarus 
similarly reported they would prefer to use traditional substances if they were available. In 
Kyrgyzstan, most respondents stated that they would never have started using NPS if opiates 
had been available on the market.  
In Georgia and Kyrgyzstan, sex workers interviewed stated that NPS help them with work 
performance (i.e. work longer hours) and to reduce fear and anxiety. In Serbia, sex workers 
generally did not have much experience with NPS and preferred to use traditional illicit 
substances or prescription drugs.  Members of the MSM community interviewed in Serbia, 
Kyrgyzstan and Kazakhstan described using NPS in the context of sexual activities, to reduce 
physical and socio-cultural inhibitions and to be part of the cultural identity of the community, 
which is also documented elsewhere in the literature in Europe (13).  Some other respondents 
in Belarus, Moldova and Kazakhstan noted NPS were more difficult to detect in urine tests, 
and therefore a reduced risk of being penalised for their use, such as sanctions for people 
currently on opioid substitution treatment (OST) programmes.   
 




Respondents in most countries (Belarus, Moldova, Georgia, Kazakhstan and Kyrgyzstan) 
described new psychoactives easy to access. NPS purchase and distribution commonly took 
place via the use of websites, social media platforms and various messaging apps.   
In Belarus, for example, people primarily accessed NPS via DarkNet drug markets (“Hydra”, 
“Koncern Kalashnikov” and “Zubr”) or through social media platforms. Participants 
sometimes received random messages on social media about purchasing NPS, or were added 
into temporary networking groups/pages. NPS websites were also advertised in the streets of 
Belarus by painting website addresses on walls. Once placing an order, the customer transferred 
funds to the administrator’s bank account, usually via ATMs. After payment, a photo of the 
terminal screen or of the paper receipt served as confirmation. Shortly after confirming 
payment, the customer received an address with a photo of a hiding place where the substance 
could be collected. Sometimes the seller also sent GPS coordinates of the pick-up location. 
Respondents noted that it took one to five hours to receive NPS purchased through this method.  
It was also possible to purchase so-called “constructors”, legal chemical components from 
which people may themselves make potent NPS using step-by-step instructions provided by 
the seller.  
The procedure described in Belarus was common in most other countries examined.  In 
Moldova, NPS sales took place through social networks such as Odnoklassniki and Instagram, 
or via fake Facebook pages with hidden IP addresses. These networks published a list of 
substances and prices called “offers”. There were also random messages sent to people via 
social networks, with the intention that these messages were circulated and eventually reached 
interested customers who would circulate them further. The Telegram application was widely 
used to sell NPS. These limited-access chat rooms or groups brought together NPS sellers and 
customers to share prices and types of NPS on the market. Once a potential customer specified 
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their location, the substance desired and quantity requested, the money transfer and delivery 
were made using the same procedure described above.  
In Georgia, new psychoactives were mainly sold through online drug markets such as Matanga 
and Party Doc, as well as through messaging apps such as Telegram, Viber and Whatsapp. 
Messages were sometimes sent randomly to people on social media apps, especially on Viber, 
mostly in Russian language, with the aim of eventually reaching interested customers.  The 
practice of direct hand-to-hand purchases of NPS was also common in Georgia. In such cases, 
middle-agents (“legs”) played the main role, as this was considered a safer way of buying NPS 
than via online markets. Respondents reported that this distribution method was typically based 
around friendships, and operated within informal social networks. 
In Kazakhstan, the most common purchase method was through Telegram or WhatsApp, using 
an electronic wallet (“kiwi”) to make payments and “zakladki”, the hidden packages delivery 
system reported in other countries in this study. Buying NPS online included a number of 
different actors playing roles in the process. In a best-case scenario, the transaction included 
four or five actors: (1) the Customer (2) the Administrator of the bot, who referred the Customer 
to (3) the Operator, with whom the Customer made the deal. As soon as payment was made, 
(4) the “Prikopper” (“zakladchik“) hid the package and the Customer received GPS coordinates 
and/or a photo of the hiding place. The Customer then either collected the package himself or 
herself, or asked (5) a “Toptun” (so-called “Legs”) to collect the hidden package on behalf of 
the Customer, in return for a share of drugs.  
Other actors could also come into play. There were “Shkurohody”, people who knew the 
locations of the usual hiding places, and could hunt for packages. In cases where neither the 
Customer nor the Toptun were able find the hidden package, they could contact the “Equal 
Shop”, which acted as a sort of customer claim centre. There were also so-called “Collectors”, 
people who tracked down unreliable customers or people who stole hidden packages.  NPS 
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were also sold face-to-face through dealers, or face-to-face with minimal human interaction, 
for example by delivering the NPS and leaving it hidden close to customer’s home. If a 
customer had a good relationship with a seller, he or she could request that substances be 
brought to their home and left in a discreet place, such as a stairwell. In some cases, it was 
possible to acquire NPS without money, in exchange for sexual services in exchange or by 
working as a “zakladchiki” (courier) paid with NPS.  
 
In Kyrgyzstan, NPS were primarily purchased online. Respondents described extensive and 
aggressive marketing of NPS through various means, including Telegram and advertising signs 
posted on walls. Young people were also recruited as “advertising agents” to distribute signs 
and posters around the city, and to act as couriers to deliver the purchases to agreed hidden 
locations where the customers could collect them. There were risks identified with online 
purchasing. These included the possibility of receiving a different substance than that ordered, 
not receiving any substance at all if an online store was fake, having the NPS stolen from the 
hiding place or being arrested while collecting the hidden package. NPS were also available 
through a “hut”, a house or flat where people could purchase and use small, single-dose 
quantities if they lack the funds or knowledge to make internet purchases.  
 
In Serbia, different groups of consumers purchased NPS in different ways. The MSM 
population, which primarily used GHB, purchased through dealers, in some cases dealers 
promoted via dating apps used by the MSM population such as Grinder. The customer called 
or messaged the seller, and the substance was delivered a few hours later to the customer’s 
address, where payment was made. Other substances, such as PCP and mephedrone, were 
described as being brought into Serbia from abroad. Recreational or party users mentioned 
the ability to purchase NPS through the DarkNet. However, procurement in this manner was 
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rare because DarkNet browsers were uncommon, and because people feared that ordering 
substances to their home address could result in discovery by law enforcement. NPS were 
usually ordered in this fashion only if there was an option to send it to a safe address. Some 
respondents also reported that they obtained NPS through friends and acquaintances who 
either ordered these substances online with the help of someone else, or brought them in from 
abroad. 
These methods of purchasing NPS were not without risks. In Belarus, police were a concern 
when buying though online channels. Law enforcement agencies sometimes created false 
DarkNet pages and arrested people seeking to purchase NPS. Also, if a person was in 
possession of a bank receipt with confirmation of payment during a police stop and search, it 
could be used it as justification for their arrest. It was reported that police sometimes used 
violence against people during arrest. After a person was taken into custody, pressure could be 
applied to coerce information on dealers. If a person refused to provide the information, he or 
she might be beaten by the police. In Georgia, almost all participants reported fear of being 
caught by the police.  As in Belarus, law enforcement agencies created false accounts in online 
drug marketplaces and arrested people looking for NPS. Respondents also said that police 
could also break into or identify a user’s account/IP address and then arrest them at the location 
where she or he is collecting the NPS. In Kyrgyzstan, respondents identified the risk of being 
arrested when collecting the NPS package from its hiding place. 
  
Impacts, risks, and consequences of NPS use 
 
In all countries, respondents identified a number of risks or consequences from NPS use. In 
Belarus, the most common negative consequences associated with NPS were psychological in 
nature, and included paranoia, hallucinations, panic attacks, psychosis, aggression and suicidal 
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thoughts. Negative physiological consequences mentioned by respondents included overdose, 
eye-gouging, motor disorders, high blood pressure and heart attacks, and well as injecting 
related harms such as vein damage and endocarditis.  Almost all interviewees mentioned an 
increase in unprotected sexual contacts. Participants also mentioned the risk of hepatitis C and 
HIV, particularly during long drug use sessions, during which people might inject from ten to 
fifteen times, sometimes sharing injecting equipment.  
In Moldova, focus groups reported a number of potential harms from NPS use including 
paranoia, panic attacks, convulsions, overdose, unprotected sexual intercourse, physical and 
mental exhaustion and psychotic conditions. Respondents who used NPS also indicated that 
strokes and heart attacks could occur as a result of high blood pressure when using synthetic 
drugs.  Others reported harms included unsafe injecting practices (heightened due to the 
frequency of injecting NPS), injecting-related vein damage and bacterial infections and risk of 
blood-borne virus transmission. Focus group participants also identified non-medical risks of 
NPS, including police pressure applied to people who use NPS in order to turn consumers into 
informants.  
In Georgia, the main risk identified by the vast majority of respondents was overdose. This risk 
was heightened because people often purchased one substance that turned out to be something 
else. Respondents identified numerous symptoms of NPS overdose. For synthetic cannabinoids 
these included lockjaw, decreased heart rate, sweating, seizures, confused consciousness and 
fainting. For synthetic cathinones, symptoms included hyperthermia, increased heart rate and 
blood pressure, coordination problems, sweating, shaking, panic attacks, hallucinations and 
skin (particularly the face) turning gray. 
 
In Kazakhstan, focus groups and service providers identified various harms related to NPS use, 
including unsafe injecting and unprotected sexual contacts. Other harms reported included 
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hallucinations, schizophrenia, paranoia, psychosis, panic attacks, suicidal behaviour, 
aggression, insomnia, encephalopathy, dehydration, injecting related infections and abscesses, 
hypoventilation, heart problems and stroke and shortness of breath.  In Kyrgyzstan, focus 
groups identified harms that included frequent injections and shared injecting equipment, lack 
of appetite and weight loss, unprotected sexual contacts, physical and psychological 
exhaustion, psychosis, paranoia, depression, heart attack and stroke and suicidal thoughts and 
actions. Respondents noted the appearance of more negative states of mind, such as anxiety, 
hallucinations and paranoia, when NPS were used in high doses and with greater frequency.  
 
In Serbia, most of the respondents’ experience related to the use of GHB, and they identified 
negative reactions including vomiting, difficulty breathing and unprotected sexual contacts. 
Harm reduction service providers described heart palpitations and overheating as other 
potential negative effects, although they noted reactions varied by substance consumed. 
Respondents generally expressed concern about the unknown composition of substances, and 
the overall lack of reliable information on dosage and effects.  This lack of knowledge was 
described as applying to both consumers and sellers of NPS. 
 
Overdoses and response 
 
 
Respondents in all countries described concerns about the dangers of NPS overdose, and 
described various physical and psychological symptoms. In Moldova, for example, focus group 
participants described symptoms of a “salts” overdose. The person may initially become very 
agitated and confused, and may faint. Their body temperature rose and the person experienced 
fluctuating blood pressure, increased heart rate and pressure and pain in the chest area. Their 
mental state was characterised as aggressive and panicked. In the case of “salts”, death might 
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occur either from heart failure or cerebral edema. If a person overdosed on “salts” and spent 
20 minutes in that condition, it was unlikely they could be saved. All focus group participants 
in Moldova who used NPS knew of one or two cases of fatal “salts” overdose.  
Respondents in all countries described a lack of knowledge an information of medically 
approved responses to NPS overdose, resulting in people who use drugs taking various 
actions themselves. In Belarus, respondents reported using artificial respiration, providing 
sugar water, dousing the person with water, staying with the person to calm them down (in 
cases panic attack or paranoia), and even tying a person down for some time in cases of 
psychosis and opening/cutting veins to let the blood flow out to lower blood pressure. 
Similarly in Georgia, the most common responses included artificial respiration, dousing the 
person with water, laying the person in recovery position, providing lemon water and staying 
with the person to calm them.  Respondents in the other four countries all described similar 
types of responses to respond to overdose. Respondents from the MSM community in Serbia 
described a common system of mutual care that had evolved in sex party settings, in which 
one person kept a record of the type of substances, times and doses for all the people at the 
party, in case any problems arose.  
Despite the common experience of overdose risk and the lack of medically appropriate 
responses, respondents in most countries expressed a reluctance to call an ambulance due to 
the impact of repressive laws and policies. Only in Moldova and Georgia did people who use 
drugs identify calling an ambulance as a standard overdose response. Most respondents in 
Belarus said that they would like to call an ambulance, but in most of the cases would not 
because of repressive drug laws. In cases of fatal overdose, police could interpret a person’s 
presence at the scene as evidence she or he was involved in drug distribution.  Therefore, the 
person who called the ambulance could be prosecuted and potentially receive a lengthy 
sentence.  In Kyrgyzstan, respondents were reluctant to call an ambulance due to fear of police, 
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including fear of human rights violations and of police taking photos and videos of the person 
and sharing them publicly.  Similarly in Serbia, people who use drugs did not typically call an 
ambulance as it would also summon police to the scene, and anyone present might be arrested 
for possession of an illegal substance. In Kazakhstan, respondents stated that if an ambulance 
was called, it took the NPS user straight to a psychiatric unit.  
 
Harm reduction services and NPS 
 
There was a consensus among people who use drugs and service providers in all countries that 
the existing harm reduction services, while important, did not meet the needs people who use 
new psychoactives. Harm reduction services and people who use NPS noted the importance of 
supplementing existing harm reduction programmes, and identified a number of necessary 
services.  Commonly cited interventions included services/paraphernalia for NPS smokers and 
other non-injectors, provision of more diverse injecting supplies, specific information on NPS 
use and risks, peer-based programmes, drug checking services and training on NPS for harm 
reduction and health workers.  The need for increased meaningful involvement of people who 
use drugs in designing new services was also identified. 
Service providers interviewed commonly identified the need to implement new harm reduction 
approaches that included peer-based interventions, case management and social/outreach 
support and services that respond to the needs of non-injecting (including NPS) users. Some 
suggested that new harm reduction approaches for non-injectors be implemented independent 
of existing services, which they considered unable to attract non-injecting (especially young) 
users to their services. At the same time, they noted that services for non-injectors should also 
be integrated into existing services. Harm reduction service providers identified the need for 




Respondents in some countries identified policy reforms necessary to enhance the harm 
reduction response. In Moldova, injecting drug use was mandatory for inclusion in a harm 
reduction programme, meaning people who used NPS non-intravenously were not able to 
register as a client, and not able to access services. The reason for this was identified as the 
criteria of the National Program for the Prevention and Control of HIV/AIDS and STIs, which 
exclusively targets prevention programmes for people who inject drugs. Harm reduction 
funding allocated to Moldova by the Global Fund to Fight AIDS, Tuberculosis and Malaria for 
2018—2020 was directed exclusively towards injecting drug use. This resulted in organisations 
that provide harm reduction services in Moldova being unable to adapt their services to trends 
on NPS use.  
 
Reform of punitive drug policies was also identified as necessary to improve the health and 
harm reduction response. In both Kazakhstan and Kyrgyzstan, fear of being placed on the 
Narcological Register deterred people from seeking medical help or accessing drug treatment 
services. The Narcological Register (also known as drug registry) registers drug users in the 
country, and includes people diagnosed with an addiction, or even if they are suspected of using 
drugs (i.e. from a positive urine test). People included on the registry are deprived of some 
rights, such as driving a car, working in certain jobs or getting into university for some studies. 
Persons listed on the register are often subjected to increased scrutiny for drug use. Depending 
on the country, placement on the register can last from 3—5 years.  
 
In Belarus, some people avoided using harm reduction services because they feared a loss of 
confidentiality and that their names would end up in the hands of law enforcement. In these 
cases, people purchased injection equipment themselves from pharmacies. In Kazakhstan, 
treatment protocols prohibited people who used both opioids and NPS from receiving OST 
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treatment. However, it was common for former or current opiate users to use NPS when 
traditional opioids were unavailable, and poly-drug drug use (usually opioids mixed with any 
other drug) was a significant issue. 
 
Suggestions for improving existing of harm reduction services included: 
Country Harm Reduction Service Needs Identified 
 
Belarus 
Needles and syringes (different sized needles, syringes of different colours to 
assist people in identifying their own syringe in circumstances where several 
people were using together); Disinfectants;  Wound care kits; More alcohol 
swabs; Vending machines with safe injection kits; Condom distribution; 
Lights to detect veins; More information on NPS (leaflets, booklets on 
different NPS, risks and safer use, information on overdose and treatment); 
Pipes for smoking; Psychological help and support; Training for narcologists 
and emergency doctors on NPS (overdose, treatment, etc.); Stronger 
cooperation among NGOs and health services 
 
Moldova 
Pipes/mouthpieces for smoking; Sterile water to dilute salts and to prevent 
dehydration; Blood pressure control as a part of harm reduction programmes; 
Information materials on the use of NPS and its risks and consequences; 
Support groups for people who use NPS and their families; Training on NPS 
for harm reduction programs, narcologists, and emergency doctors; 
Collaboration of harm reduction programmes with emergency medical 
services (ambulances); Increased funding of harm reduction programmes to 
allow the development and implementation of services for non-injectors.   
Georgia Pipes for smoking; foils for smoking or inhaling; Paper tubes and cards to 
create smooth surfaces and lines for snorting; Drug checking services; Peer-
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based interventions/programmes; Information materials on the use of NPS and 
its risks and consequences; Training on NPS for harm reduction programmes. 
 
Kazakhstan 
More diverse drug paraphernalia (pipes for smoking, filters, sterile water, tin 
foil, cookers, insulin syringes, pipettes for smoking); Vitamins; Ointments and 
bandages; Easier access to antidepressants and sleeping pills; Safe spaces with 
compassionate professionals to support NPS users; Information and training 
on NPS-related issues, risks and harm; Rights-based training to assist people 
who use drugs in understanding their rights  
 
Kyrgyzstan 
 Psychological and housing supports; Peer support; Information and 
educational materials on NPS use, risks, overdose; Paraphernalia relevant to 
the needs of people who use NPS, including pipes, vaseline, condoms, 
lubricants, foil; Strategies to engage hard-to-reach groups, such as young 
people who have never used traditional harm reduction services, and people 
who are purchasing drugs online; Mapping existing harm reduction services in 
a database of them, so that anyone who needs help or support can find all the 
relevant information on one website or app. 
Serbia Drug checking services, particularly in places where young people congregate 
and socialise, such as clubs and festivals, as well as home test kits 
 
Discussion 
This is the first study to examine the use of new psychoactive substances and the harm 
reduction response in Belarus, Moldova, Serbia, Kazakhstan, Kyrgyzstan and Georgia. The 
study is unique both in its focus on recording lived experience of people who use drugs and 
people who provide harm reduction services, and its cross-national nature in a region that 
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otherwise has produced little data on NPS.  Despite their cultural and political differences, 
and the various sub-regions in which the countries are situated, the study found remarkable 
similarities in patterns of NPS use and risk behaviours, markets and harm reduction gaps.  
The study identified a several common patterns of NPS use and related harms that are worthy 
of discussion and further attention.   
The first is the role of injecting and related risk. Injecting NPS was reported to be a 
significant practice in Belarus, Moldova, Georgia, Kazakhstan and Kyrgystan, and most 
likely to occur among people who have previous history of injecting opioids. Respondents 
commonly described injecting NPS as characterised by short highs and frequent injections.  
This is consistent with research from other CEECA countries that found increased injecting 
episodes per day and increased sharing of injecting equipment among people who inject NPS 
(12, 15). Increased frequency of injecting is linked to increased risk of blood-borne virus 
transmission and other injecting-related harms (30). Serbia was the only country in the study 
in which injecting NPS was as rare, in which the profile of NPS user was closer to the 
recreational profile of NPS users in Western Europe (10).  
The study identified a number of common reasons for choosing NPS rather than traditional 
illicit drugs.  The primary reasons given by respondents was the lower cost of NPS and ease of 
accessibility.  For respondents with previous histories of illicit drug use, which was the cohort 
most likely to inject NPS, accessibility was linked to trends in the drug market.  Respondents 
in Belarus, Moldova, Georgia, Kazakhstan and Kyrgystan all described using NPS as 
substitutes when their traditional drug of choice (typically opioids) was not available.  In 
general, these respondents expressed a preference for the traditional substances they used, 
rather than the NPS. In many cases, respondents reported they would not use NPS at all if 
traditional opiates were available.  This is the first time this trend has been documented in these 
29 
 
countries, and is a finding consistent with several other European studies that have linked NPS 
injecting to decreased heroin availability (15, 31, 32, 33, 34).   
The study identified significant common gaps in the harm reduction response. Researchers 
identified concern about NPS overdose in all countries, a concern heightened by a lack of 
reliable information on the effects of NPS, symptoms of NPS overdose and medically 
appropriate responses to NPS overdose. As a result, overdose response was typically provided 
by people who use drugs themselves, who used a variety of interventions to assist the person 
in distress. Respondents in all countries agreed that current harm reduction services were 
important. However, they also identified the need to enhance and expand those services in the 
context of NPS.  Services and supplies for non-injectors, information of NPS effects and 
medically correct overdose responses, drug checking services, peer support and training for 
harm reduction and health workers on new psychoactives were commonly identified. 
Meaningful involvement of people who use NPS was identified as a key need in developing 
new services and interventions. 
An overarching theme that emerged in all countries was the role of punitive drug policies in 
driving NPS use and related harms. The negative impacts of punitive laws and policies on HIV 
prevention and treatment is well documented (35). This study found crackdowns on traditional 
drug markets (i.e. heroin, cannabis, etc.), resulting in shrinking availability and higher prices, 
influenced the decision of many people who use drugs to substitute their drug of choice for 
cheaper and more accessible synthetic substances.  However, this had the effect of driving 
people towards more risky substances, the effects of which were often unknown, and the harm 
reduction/overdose responses unclear. For synthetic cannabinoids, people reported a variety of 
harmful psychological effects not typically found with the use of cannabis. For synthetic 
cathinones, the short acting nature the euphoria led to an increased frequency of injecting, 
heightening the likelihood of unsafe injecting practices, injecting related harms and 
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transmission of blood-borne viruses. Respondents in Belarus, Moldova and Kazakhstan 
identified the desire to evade sanctions for positive drug tests as a reason for using NPS, again 
suggesting punitive drug polices as driving the new of new psychoactives. 
 
Punitive drug polices had other negative impacts on the health response to NPS. People who 
use drugs in Belarus, Kazakhstan, Kyrgyzstan and Serbia expressed reluctance to call an 
ambulance in the case of overdose because of the likelihood of police responding with the 
ambulance, putting the people present at risk of arrest. This fear was further exacerbated by 
violent police practices reported in some countries, committed either during arrest or later while 
in custody to try and compel information.   Respondents in Kazakhstan and Kyrgyzstan also 
identified the fear of being placed on Narcological Register, and the punitive impacts of such 
a placement, as a deterrent to calling ambulances in the case of overdose, and accessing medical 
care or drug treatment services. In Belarus, some people who use drug expressed reluctance to 
access harm reduction services for fear of being identified by police. 
Conclusion 
This study represents the first detailed, multi-country investigation of NPS use, markets and 
the harm reduction response in the Eurasian region. It makes an important contribution to the 
scarce information on the use of NPS in the six focus countries, and highlights the need for 
enhancing the harm reduction response in the region, including the removal of punitive drug 
policies. It also points the way for further research on new psychoactive substances and harm 
reduction in the region. 
 
List of abbreviations 
31 
 
ATM: Automatic Teller Machine 
CEECA: Central and Eastern Europe and Central Asia.  
EHRA: Eurasian Harm Reduction Association.  
EK: Eliza Kurcevič.  
MSM: Men who have Sex with Men.  
NPS: New/Novel Psychoactive Substance(s). 
OST: Opioid Substitution Treatment. 
RL: Rick Lines 
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